Programs & Research
Our pipeline of product candidates offers opportunities to advance novel treatments across diverse therapeutic areas and mechanisms of action with the potential to transform the treatment landscape for brain health disorders.
Science of MM120
MM120 orally disintegrating tablet (ODT) is MindMed’s proprietary and pharmaceutically optimized form of lysergide D-tartrate (LSD). MM120 is a synthetic ergotamine belonging to the group of classic, or serotonergic, psychedelics, which acts as a partial agonist at specific serotonin receptors, causing its distinctive transient perceptual and emotional effects.
MM120 increases connections between areas of the brain that aren’t normally connected, enabling changes that could treat depression, anxiety and other brain health disorders.
In clinical trials, MM120 has shown positive effects in reducing symptoms of anxiety and depression after just a single administration. These effects can be rapid and durable, beginning as quickly as the day after treatment and maintaining for at least 3 months.1
- Paula L. Jacobsen, PhD; Jamie M. Freedman, BS; Jamileh Jamison, MD, MS; Sarah M. Karas, PsyD; Daniel R. Karlin, MD, MA; Reid Robison, MD (2024). Rapid and Durable Response to a Single Dose of MM120 (Lysergide) in Generalized Anxiety Disorder: A Dose Optimization Study.
MM120 ODT | Lysergide D-tartrate (LSD)
Lead Candidate with Potential Benefits Across Multiple Therapeutic Areas, Including Generalized Anxiety Disorder (GAD) and Major Depressive Disorder (MDD)
MM120 orally disintegrating tablet (ODT) is MindMed’s proprietary and pharmaceutically optimized form of lysergide D-tartrate, which is also known as LSD. MM120 ODT is an advanced formulation incorporating Catalent’s Zydis® fast-dissolve technology, which has a unique clinical profile with rapid absorption, improved bioavailability, and reduced gastrointestinal side effects.
Based on the significant unmet medical need in the treatment of GAD and the clinical data from MindMed’s Phase 2b study, the U.S. Food & Drug Administration has granted Breakthrough Therapy Designation for the MM120 program in GAD.
Key Highlights of MM120 Phase 2b Study
MM120 was Well-tolerated with Mostly Transient, Mild-to-Moderate Adverse Events (AEs) Consistent with Drug Class Expectations1
MM120 ODT for GAD | Phase 3 Study Designs
Two Phase 3 registrational trials will evaluate the efficacy and safety of MM120 ODT in the treatment of adults living with GAD versus placebo. The first, the Voyage study, is expected to enroll approximately 200 participants in the U.S. The Panorama study, the second Phase 3 trial, will be conducted in the U.S. and Europe, is expected to enroll 240 participants.
MM120 ODT for MDD | Phase 3 Study Design
Emerge, a Phase 3 registrational trial, will evaluate the efficacy and safety of MM120 ODT in the treatment of adults living with MDD versus placebo. Emerge is expected to enroll approximately 140 participants in the U.S. A second registrational study in MDD is expected to be conducted, with the study design and timing to be informed by the results from Emerge and additional regulatory discussions.
MM402 | R(-)-MDMA
Clinical Data Support Opportunity in Autism Spectrum Disorder (ASD)
MM402, or R(-)-MDMA, is under development to treat the core symptoms of ASD. Results from preliminary clinical studies suggest MM402 is well-tolerated and is pharmacologically active with a mechanism that could enhance social and communication skills in individuals with ASD. Preclinical study results of MM402 in animal models demonstrate acute and durable positive effects on social functioning in the ASD population, which suggests that MM402 may have1:
